الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
Irritable bowel syndrome is a functional gastrointestinal disorder that occurs without any organic cause. It is characterized by chronic or recurrent abdominal pain associated with either relief or exacerbation by defecation, or a change in bowel habit. The pathogenesis of the disease has not been clearly understood, and several factors, such as psychosocial stress, alteration of serotonin signaling, mast cells, brain-gut axis, low-grade inflammation, microbiota, barrier dysfunction on mucosal surfaces, and immune reaction to food are thought to be related to this condition. Atopic dermatitis (AD) is an inflammatory and heterogeneous skin disease. It is characterized by pruritus and recurrent eczematous reaction that has chronic disease course. Atopic dermatitis has a complex pathogenesis depends on the interaction between environmental and genetic factors ending in disturbances in the immune system and disruption of the epidermal barrier. The studies have provided some insight that IBS patients are indeed more likely to suffer from certain skin conditions such as atopic dermatitis. Both atopic dermatitis and IBS are brought about by immune dysregulation in genetically susceptible hosts. The aim was to study the potential link between atopic dermatitis and irritable bowel syndrome. This case control study was conducted on 140 subjects, who were divided into two groups, group (1) included 70 cases of irritable bowel syndrome, group (2) included 70 apparently healthy subjects of matched age and sex, who were chosen as a control. Patients were selected from the outpatient clinics of internal medicine department, Menoufia University Hospital, during the period from February 2022 to October 2022. Studied groups were subjected to complete history taking. Both general and dermatological examination were performed. Patients with IBS were diagnosed using Roman IV. Determination of atopic dermatitis severity using Eczema Area Scoring Index (EASI). SCORAD (SCORing Atopic Dermatitis) used to assess the extent and severity of eczema. Dermatology Life Quality Index was utilized to measure how much patient skin problem has affected his life over the last week. Pruritus intensity score was utilized to assign a numerical score representing the intensity of patient´s itching on a scale from 0 to 10. The results of the current study can be summarized as the following: • There was no significant differences between cases and controls regarding their socio- demographic data. • There was significant difference between irritable bowel syndrome patients and controls regarding family history of atopic dermatitis, about 11(15.4%) of patients had positive family history while only 6 (4.3%) of controls (P value 0.024). • Atopic dermatitis was higher in patients with irritable bowel syndrome 17(24.3%) versus 6(8.6%) in controls (P value 0.012). • There was no significant difference between cases with AD and controls with AD regarding onset, course, duration of disease,dermatology life quality index, pruritus intensity score, scoring atopic dermatitis (SCORAD) and Eczema Area Scoring Index (EASI). • Family history of IBS was positive in 43 (61.4%) and was negative in 27 (38.6%) of cases. • Onset of the disease was sudden in 41 (58.6%) and gradual in 29 (41.4%) of cases. • Disease duration ranged from 7months - 40 years with 10.2±8.83 months as a mean±SD value. • Regarding number of bowel movement per day ranged from 1 – 5 with 2.55±0.95 as a mean±SD value. • There was significant positive correlation between scoring atopic dermatitis and eczema area scoring index (P =0.001). • No significant correlation between scoring atopic dermatitis (SCORAD) and age, disease duration, pruritus intensity score and bowel movement per day of studied cases(P >0.05). • More than half of Patients with atopic dermatitis (52.9%) had positive family history of the disease(P value 0.001). • That there was no significant relation between presence of atopic dermatitis and clinical data of the studied IBS patients (P value > 0.05).